---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-26-000015"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:47:51.600255+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moderna Q4 revenue $678M (-30% YoY); net loss $(826)M; FY2025 net loss $(2.8)B

## Summary
- Q4 2025 revenue $678M (-30% YoY); GAAP net loss $(826)M ($(2.11) EPS).
- Full-year 2025 revenue $1.9B (-40% YoY); net loss $(2.8)B ($(7.26) EPS).
- 2026 guidance: up to 10% revenue growth; R&D ~$3.0B; year-end cash $5.5-6.0B.
- U.S. FDA issued Refusal-to-File for seasonal flu vaccine (mRNA-1010); Moderna requested Type A meeting.
- Norovirus Phase 3 fully enrolled; intismeran autogene Phase 2 bladder cancer fully enrolled; data readouts expected 2026.

## SEC filing metadata
- accession: 0001682852-26-000015
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/0001682852-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/mrna-20260213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-26-000015
- JSON: https://secwatch.observer/filing/0001682852-26-000015.json
- Plain text: https://secwatch.observer/filing/0001682852-26-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.